"label","id","rationale","uuid:ID","description","name"
"","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","a4f80715-4e5c-4f60-88df-13154c40f197","The main design for the study","Study Design 1"
